Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start - Episode 6

Treatment Resistance in HIV

Published on: May 31, 2024

Paul E. Sax, MD, Shauna Applin, ARNP, Sorana Segal-Maurer, MD, Lakecia Pitts, MD, MBA

Paul E. Sax, MD, and Sorana Segal-Maurer, MD, discuss treatment resistance in HIV and how it has changed over the years.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: The Role of the Primary Care Provider/Advanced Practice Provider in HIV Management

EP. 2: Evolving Treatment Practices and Guidelines for HIV

EP. 3: Key Clinical Considerations in HIV Treatment Decisions

EP. 4: HIV Treatment: Discussing Adverse Events with Patients

EP. 5: Importance of Starting HIV Treatment Early

EP. 6: Treatment Resistance in HIV

EP. 7: HIV Drug Resistance Testing Practices and Patient Education

EP. 8: Managing Suboptimal Adherence to HIV Medications

EP. 9: HIV Treatment Clinical Experiences

EP. 10: Addressing Suboptimal Treatment Response in HIV

EP. 11: Current HIV Treatment Regimens

EP. 12: Rapid Treatment Initiation in HIV

EP. 13: Switching Therapies for Patients with HIV and History of Resistance

EP. 14: Resources Available for Patients with HIV Drug Resistance

EP. 15: Factors that Inform Treatment Selection in HIV

EP. 16: Switching Therapies in HIV

EP. 17: Restarting Therapy in Patients with HIV

EP. 18: Treatment Guidelines and Regimens for Managing Patients with HIV

EP. 19: Differences in Binding Affinity Between Integrase Inhibitors in HIV

EP. 20: Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens

EP. 21: Recent Studies on HIV Treatments and Patient-Reported Outcomes

EP. 22: HIV: Treating Patients with Viral Mutations

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question:

When we are talking about treatment resistance in HIV, what do we mean?
Impact of drug resistance on the disease course
Impact on the achievement of global targets
- Most common mutations
How has resistance in HIV treatment changed over the years?
FDA approvals have provided options for those with resistance.

Advertisement

Advertisement

Advertisement

x